Hopitaux Prives De Metz

The department of Internal Medicine at Hopitaux Prives De Metz is advancing therapies for conditions driven by abnormal immune activity, such as giant cell arteritis and rapidly progressive glomerulonephritis.

• Evaluating targeted biologics to reduce relapse in vasculitis.
• Assessing safety of continuous IV infusion for kidney inflammation.
• Exploring immunomodulatory strategies to preserve organ function.

These studies aim to improve long‑term outcomes and quality of life for patients with autoimmune disorders by testing new treatment approaches and monitoring disease markers.

Research at the site focuses on progressive lung conditions, including idiopathic pulmonary fibrosis, interstitial lung disease, and metastatic non‑small cell lung cancer.

• Measuring the impact of novel oral agents on lung capacity.
• Testing rituximab versus placebo to stabilize lung function.
• Comparing combination immunotherapy and chemotherapy regimens for advanced lung cancer.

The goal is to slow disease progression, maintain breathing ability, and extend survival for patients facing serious respiratory illnesses.

The clinical program includes several cancer trials targeting bladder, colon, breast, and lung malignancies, with a strong emphasis on personalized treatment strategies.

• Investigating peri‑operative pembrolizumab combined with chemotherapy for muscle‑invasive bladder cancer.
• Assessing peptide‑based vaccines in HER2‑positive breast cancer with residual disease.
• Evaluating targeted antibody combinations for metastatic non‑small cell lung cancer.
• Studying ctDNA‑guided chemotherapy decisions after colorectal surgery.

These investigations seek to enhance cure rates, reduce recurrence, and tailor therapy based on tumor biology and genetic markers.

Within the digestive tract arena, the centre conducts trials on colon carcinoma and related gastrointestinal cancers, aiming to refine post‑surgical management.

• Using circulating tumor DNA to guide adjuvant chemotherapy decisions.
• Testing the efficacy of combined immunotherapy and anti‑angiogenic agents in advanced colorectal disease.

The research prioritizes reducing metastatic risk and improving survival through innovative therapeutic combinations and precision monitoring.

Although the current portfolio emphasizes oncology and immune disorders, the facility maintains expertise in managing complex infections, supporting future trial development in this field.

• Readiness to evaluate novel antimicrobial agents in hospital‑acquired infections.
• Potential collaboration on antifungal therapy studies for immunocompromised patients.

Ongoing preparedness ensures that the site can rapidly launch infection‑focused studies when opportunities arise, complementing its broader clinical research mission.